Last reviewed · How we verify
Ultrix Quadri
Ultrix Quadri is a combination of four anti-arrhythmic medications used to treat atrial fibrillation.
Ultrix Quadri is a combination of four anti-arrhythmic medications used to treat atrial fibrillation. Used for Atrial fibrillation for stroke prevention, Atrial fibrillation for rate control.
At a glance
| Generic name | Ultrix Quadri |
|---|---|
| Sponsor | Samara Regional Cardiology Dispensary |
| Drug class | anti-arrhythmic |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
It combines amiodarone, sotalol, propafenone, and dronedarone to manage irregular heart rhythms. This combination aims to provide a more effective treatment option for patients with atrial fibrillation.
Approved indications
- Atrial fibrillation for stroke prevention
- Atrial fibrillation for rate control
Common side effects
- QT interval prolongation
- Bradycardia
- Torsades de pointes
Key clinical trials
- Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine (PHASE2, PHASE3)
- Influenza Vaccination During Coronavirus Disease 2019 Outbreak After Acute Coronary Syndrome and Chronic Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |